aTyr Pharma (NASDAQ:ATYR – Get Free Report) and Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.
Analyst Recommendations
This is a summary of recent recommendations for aTyr Pharma and Abeona Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| aTyr Pharma | 1 | 5 | 1 | 1 | 2.25 |
| Abeona Therapeutics | 1 | 0 | 2 | 0 | 2.33 |
Abeona Therapeutics has a consensus price target of $19.33, indicating a potential upside of 257.36%. Given Abeona Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than aTyr Pharma.
Volatility and Risk
Earnings and Valuation
This table compares aTyr Pharma and Abeona Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| aTyr Pharma | $190,000.00 | 221.88 | -$74.12 million | ($0.62) | -0.69 |
| Abeona Therapeutics | $5.82 million | 53.15 | $71.18 million | ($1.09) | -4.96 |
Abeona Therapeutics has higher revenue and earnings than aTyr Pharma. Abeona Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares aTyr Pharma and Abeona Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| aTyr Pharma | N/A | -95.89% | -69.67% |
| Abeona Therapeutics | N/A | -41.69% | -30.36% |
Insider and Institutional Ownership
61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Abeona Therapeutics beats aTyr Pharma on 10 of the 14 factors compared between the two stocks.
About aTyr Pharma
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
About Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
